Search
Now showing items 1-1 of 1
Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia.
(2021-12-21)
Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death ligand 1 (PD-L1) inhibitor, ...